Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable securities - available-for-sale debt securities

Marketable securities - available-for-sale debt securities

9 Months Ended

Sep. 30, 2021

Marketable securities - available-for-sale debt securities

Marketable securities - available-for-sale debt securities

Note 7 — Marketable securities – available-for-sale debt securities

As of September 30, 2021, the Company has the following investments in marketable securities (in thousands):


				Gross		Gross		Aggregate
	Remaining	Amortized		Unrealized		Unrealized		Estimated
	Contractual Maturity	Cost		Gains		Losses		Fair Value
Available-for-sale debt securities:
Corporate debt securities	Less than 3 months	$	9,228	$	5	$	(1)	$	9,232
Corporate debt securities	3 months to 1 year		135,761		104		(29)		135,836
Corporate debt securities	1 year to 2 years		52,189		14		(69)		52,134
		$	197,178	$	123	$	(99)	$	197,202

The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of September 30, 2021 and 31 December, 2020 are as follows:



	September 30, 2021						December 31, 2020
	Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses		Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses
Marketable securities:
Corporate debt securities	$	85,165		15	$	(99)	$	157,985		30	$	(158)

As of September 30, 2021, the securities in an unrealized loss position are not considered to be other than temporarily impaired because the impairments are not severe and have been for a short duration. No securities have been in an unrealized loss position for more than one year. The Company does not intend to sell the debt securities in an unrealized loss position and believes that it has the ability to hold the debt securities to maturity.